<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310411</url>
  </required_header>
  <id_info>
    <org_study_id>16926</org_study_id>
    <secondary_id>H8H-MC-LAHU</secondary_id>
    <nct_id>NCT03310411</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Four-Period, Crossover Study to Evaluate the Cardiovascular Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether taking lasmiditan and sumatriptan together
      will have any additional effects on heart rate and blood pressure compared to taking
      lasmiditan and sumatriptan individually. This study will also look at the amount of study
      drug that gets into the blood stream and how long it takes the body to get rid of it when
      these two drugs are taken together.

      This study will last about 21 days, not including the screening. Participants will spend 16
      days/15 nights in the clinical research unit (CRU) followed by follow-up. Screening is
      required within 28 days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">December 23, 2017</completion_date>
  <primary_completion_date type="Actual">December 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics (PD): Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline through 24 hours after administration of study drug in each period</time_frame>
    <description>Systolic Blood Pressure (SBP) per 24-hour Ambulatory Blood Pressure Monitoring (ABPM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan, Sumatriptan, and Lasmiditan + Sumatriptan</measure>
    <time_frame>Baseline through 48 hours after administration of study drug in each period</time_frame>
    <description>PK: Cmax of Lasmiditan, Sumatriptan, and Lasmiditan + Sumatriptan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC[0 ∞]) of Lasmiditan, Sumatriptan, and Lasmiditan + Sumatriptan</measure>
    <time_frame>Baseline through 48 hours after administration of study drug in each period</time_frame>
    <description>PK: AUC(0 ∞) of Lasmiditan, Sumatriptan and Lasmiditan + Sumatriptan</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lasmiditan + Sumatriptan (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of lasmiditan and single oral dose of sumatriptan in one of four treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan + Placebo (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of lasmiditan and single oral dose of placebo in one of four treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sumatriptan + Placebo (C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose of sumatriptan and single oral dose of placebo in one of four treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Placebo (D)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral doses of placebo in one of four treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan + Sumatriptan (A)</arm_group_label>
    <arm_group_label>Lasmiditan + Placebo (B)</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan + Sumatriptan (A)</arm_group_label>
    <arm_group_label>Sumatriptan + Placebo (C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Lasmiditan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Sumatriptan + Placebo (C)</arm_group_label>
    <arm_group_label>Placebo + Placebo (D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Sumatriptan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan + Placebo (B)</arm_group_label>
    <arm_group_label>Placebo + Placebo (D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Have a body mass index of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive

        Exclusion Criteria:

          -  Have known allergies to Lasmiditan, Sumatriptan, related compounds, or any components
             of the formulations of Lasmiditan and Sumatriptan

          -  Have a history of, or electrocardiogram (ECG) findings of, clinically significant
             bradycardia, heart block, tachy or brady arrhythmias

          -  Have a history, signs, or symptoms of arrhythmia or Wolff Parkinson White syndrome
             that could affect the participant's safety

          -  Have an estimated glomerular filtration rate (eGFR) of less than (&lt;) 60 milliliter per
             minute (mL/min) per 1.73 m²

          -  Have a resting systolic blood pressure (SBP) greater than (&gt;) 135 millimeters of
             mercury (mmHg) and diastolic blood pressure (DBP) &gt;85 mmHg at screening

          -  Have a supine pulse rate (PR) of &lt;50 or &gt;90 beats per minute (bpm) at screening

          -  Have a history, signs, or symptoms of vasospastic coronary artery disease

          -  Have known or ongoing neuropsychiatric disorders (for example, manic depressive
             illness, schizophrenia, depression) considered as clinically significant by the
             investigator

          -  Use of monoamine oxidase-A inhibitors and other drugs associated with serotonin within
             the 3 months prior to the first dosing occasion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Daytona Beach</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

